HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.057281v1 50/Suppl_1/106S    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunphy, M. P.S. Articles by Lewis, J. S. Search for Related Content PubMed PubMed Citation Articles by Dunphy, M. P.S. Articles by Lewis, J. S.

Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET

¹ Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and ² Molecular Pharmacology and Chemistry, Sloan-Kettering Institute for Cancer Research, New York, New York

Correspondence: For correspondence or reprints contact: Jason S. Lewis, Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, New York 10065. E-mail: lewisj2{at}mskcc.org

This review article discusses PET agents, other than ¹⁸F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non–¹⁸F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-¹⁸F-fluoro-3'-deoxythymidine and ¹⁸F-1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as ^60/62/64Cu-labeled diacetyl-bis(N⁴-methylthiosemicarbazone) and ¹⁸F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl-¹¹C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16β-¹⁸F-fluoro-5-dihydrotestosterone and 16-¹⁸F-fluoro-17β-estradiol, respectively.

Key Words: PET • therapy monitoring • hypoxia • steroid receptors • proliferation

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]